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Background: Archival formalin-fixed paraffin-embedded (FFPE) cancer tissue samples are a readily available
resource for microRNA (miRNA) biomarker identification. No established standard for reference miRNAs in FFPE
tissue exists. We sought to identify stable reference miRNAs for normalization of miRNA expression in FFPE tissue
samples from patients with colorectal (CRC) and pancreatic (PC) cancer and to quantify the variability associated
with sample age and fixation.
Methods: High-throughput miRNA profiling results from 203 CRC and 256 PC FFPE samples as well as from 37
paired frozen/FFPE samples from nine other CRC tumors (methodological samples) were used. Candidate reference
miRNAs were identified by their correlation with global mean expression. The stability of reference genes was
analyzed according to published methods. The association between sample age and global mean miRNA
expression was tested using linear regression. Variability was described using correlation coefficients and linear
mixed effects models. Normalization effects were determined by changes in standard deviation and by hierarchical
clustering.
Results: We created lists of 20 miRNAs with the best correlation to global mean expression in each cancer type.
Nine of these miRNAs were present in both lists, and miR-103a-3p was the most stable reference miRNA for both
CRC and PC FFPE tissue. The optimal number of reference miRNAs was 4 in CRC and 10 in PC. Sample age had a
significant effect on global miRNA expression in PC (50 % reduction over 20 years) but not in CRC. Formalin fixation
for 2–6 days decreased miRNA expression 30–65 %. Normalization using global mean expression reduced variability
for technical and biological replicates while normalization using the expression of the identified reference miRNAs
reduced variability only for biological replicates. Normalization only had a minor impact on clustering results.
Conclusions: We identified suitable reference miRNAs for future miRNA expression experiments using CRC- and PC
FFPE tissue samples. Formalin fixation decreased miRNA expression considerably, while the effect of increasing
sample age was estimated to be negligible in a clinical setting.
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MicroRNAs (miRNAs) are ~22 nucleotides long non-
protein-coding RNAs involved in post-transcriptional
regulation of gene expression [1, 2]. Mature miRNAs
join the RNA-induced silencing complex (RISC) in the
cytoplasm and bind to messenger RNAs (mRNAs),
whereby they block translation or induce degradation
of the mRNA transcript. Each miRNA targets specific
genes through sequence complementarity between the
miRNAs "seed" region (nucleotides 2–7) and a miRNA
recognition element (MRE) in the mRNA, most often
located in the 3'-untranslated region (3'UTR). More
than 2,500 mature human miRNA sequences have been
annotated so far (http://www.mirbase.org) [3]. Because
of the targeting of the miRNA seed region to a specific
7-nucleotide MRE in the mRNA, each miRNA can po-
tentially regulate the expression of hundreds of genes.
Indeed, it is estimated that most of the protein-coding
genes are regulated by miRNAs [2, 4]. Accordingly,
most, if not all, developmental, physiological and dis-
ease processes, such as cancer, are regulated by miR-
NAs [5, 6]. MiRNAs are involved in all the hallmark
capabilities of cancer [7–9]. Deregulation of miRNA ex-
pression is associated with cancer development, and
changes in miRNA expression are associated with sur-
vival in patients with cancer [9].
MiRNAs have been investigated intensely as potential
biomarkers in cancer. A commonly used method for de-
termination of miRNA expression is the reverse transcrip-
tion quantitative polymerase chain reaction (RT-qPCR).
RT-qPCR can be utilized to measure either single- or mul-
tiple miRNAs per experiment. One of the most important
and challenging issues in miRNA expression experiments
is normalization. The purpose of normalization is to re-
move as much non-biological variation, "noise" and bias,
from the data as possible and to make it possible to com-
pare results within or between experiments. In large
microarray studies in which the expression of hundreds of
miRNAs is measured, global mean normalization is the
gold standard [10]. This normalization method uses the
average expression of all miRNAs in each sample for
normalization. In experiments with a smaller number of
miRNAs, global mean normalization is not an option, and
instead reference genes are needed for normalization.
Traditionally, small nuclear- or nucleolar RNAs like
RNU6B have been used for normalization in miRNA ex-
periments. Yet, these have been shown to be inferior to
the use of stably expressed global mean-associated miR-
NAs as reference genes [11–13]. Only a few studies have
identified suitable reference miRNAs for use in frozen
blood or tissue samples [10–15], and no published studies
have identified reference miRNAs in FFPE tissue in an un-
biased manner. Because miRNAs are highly tissue specific
[14], reference miRNAs need to be validated within eachtissue and tumor type, and for some prevalent malignan-
cies like pancreatic cancer (PC), no publications regarding
suitable reference miRNAs exist.
In the present study, we sought to identify stable refer-
ence miRNAs useful for normalization of RT-qPCR-
determined miRNA expression in FFPE tissue samples
from patients with colorectal cancer (CRC) and PC, and
also to quantify the sources of variability associated with
measurements of miRNA expression in archival FFPE
samples.
Methods
Cohorts and clinical data
The miRNA measurements used for identifying refer-
ence miRNAs in this paper were produced in two previ-
ously published studies of CRC and PC [16–18]. For
details regarding the clinical study populations, readers
are referred to these papers. Importantly, all of the sam-
ples used were resected before any systemic treatment
was initiated. Briefly, the 203 CRC samples (“CRC co-
hort”) were collected retrospectively from patients with
metastatic CRC (mCRC) who had started first line treat-
ment with capecitabine, oxaliplatin, and bevacizumab
from 2006 to 2011 at one of 10 departments of oncology
in Denmark. The endpoint overall survival (OS) was
measured from initiation of first-line treatment to death
from any cause. The vital status of all patients was up-
dated in July 2013. The 256 PC samples (“PC cohort”)
were retrospectively collected from patients undergoing
surgery for pancreatic ductal adenocarcinoma or ampul-
lary adenocarcinoma at the Department of Surgical
Gastroenterology, Herlev University Hospital, from 1976
to 2008. Control tissue samples from resected normal
pancreas (n = 20) and chronic pancreatitis (n = 20) were
also included. OS in this cohort was measured from sur-
gical resection to death from any cause, and participant
vital status was updated October 2010. Patients in both
cohorts who were alive at the time of last vital status up-
date were censored. The 37 methodological samples
were all from patients with CRC who had undergone
surgery at the Department of Surgical Gastroenterology
at Herlev University Hospital. The methodological sam-
ples that were used for the comparison of frozen- and
FFPE tissue were anonymized samples acquired from the
Danish CancerBiobank at Herlev University Hospital.
Tissue sample handling and -preparation
All the samples in the CRC- and PC cohorts were FFPE
samples from primary tumors handled according to the
standard procedures at each local department of pathology.
In general, resected tumor specimens were transported to
the pathology department right after surgery. The speci-
mens were then inspected and described by the pathologist,
and the tumors were fixed in 10 % formalin-fixation
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sometimes up to 5 days. After fixation, tumors sections
were embedded in paraffin, and then stored at room
temperature in a dry environment.
A collection of methodological samples from nine dif-
ferent CRC tumors was also used. These samples were
treated differently: frozen or formalin fixed and paraffin
embedded and serially sectioned. Within 30 minutes
after surgery, tumor tissue was partitioned into three or
four sections. One tumor section was immediately fro-
zen in liquid isopentane. When frozen, the tumor was
transferred to a container and kept in the freezer at -80 °
C. The remaining tumor sections were fixed in formalin
for 2, 3, or 6 days and then embedded in paraffin and
kept at room temperature.
The diagnosis of carcinoma was confirmed by an experi-
enced gastro-intestinal pathologist (DL) by review of a 3-
μm hematoxylin and eosin (HE)-stained section from each
tumor block. Three 10-μm sections were then cut from
each tumor block without micro- or macro-dissection,
and the sections were placed in sterile Eppendorf tubes.
An overview of how the individual methodological sam-
ples were handled is provided in Table S1 in Additional
file 1. From tumors 1–3, adjacent FFPE sections were cut
and placed in two separate tubes. From tumors 4–9, sec-
tions were cut from both frozen samples and from FFPE
tissue samples that were fixed for 2 to 6 days. From tumor
4, additional adjacent FFPE sections were cut and placed
in five separate tubes.
The tissue sectioning was performed by experienced
laboratory technicians at the Department of Pathology,
Herlev University Hospital.
MiRNA purification
All miRNA purification and expression analyses procedures
were performed by the biotech service provider AROS
Applied Biotechnology, Aarhus, Denmark (www.arosab.-
com) using commercially available reagents. The company
was blinded to all clinical information.
For the CRC cohort and the methodological samples,
RNA was purified using the miRNeasy FFPE Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s in-
structions (miRNeasy FFPE Handbook September 2010,
www.qiagen.com). Briefly, samples were deparaffinized
and then lysed with proteinase K digestion followed by
heat treatment. After centrifugation, the supernatant was
recovered and treated with DNase. After mixing with buf-
fer and ethanol, part of the mixture was transferred to an
RNeasy MinElute spin column where total RNA was
bound. After washing, the RNA was eluted and normal-
ized to 70 ng/μl manually. For the PC cohort samples,
RNA was purified using the High Pure miRNA Isolation
Kit (Roche, Basel, Switzerland) according to the manufac-
turer’s instructions. Briefly, the tissue sections weredeparaffinized in xylene and ethanol, then treated with
proteinase K, and finally RNA was isolated using the one-
column spin column protocol for total RNA. After wash-
ing, the RNA was eluted and an aliquot was normalized to
133 ng/μl. A few samples (approximately 10) were below
133 ng/μl and were therefore concentrated by speed vac.
The purity and concentration of RNA were assessed by
absorbance spectrophotometry on a NanoDrop 8000
(Thermo Fisher Scientific, Waltham, MA, USA). Samples
with a 260/280 nm absorbance ratio below 1.8 were dis-
carded and new sections from the corresponding tissue
block were cut and purified, if possible. Purified samples
were stored at -80 °C until they were used for miRNA ex-
pression analysis.
MiRNA reverse transcription and expression analysis
The TaqMan® Array Human MicroRNA A + B Cards
Set version 3.0 (Applied Biosystems/Life Technologies,
Carlsbad, CA, USA) was used to quantify expression
of 754 miRNAs in the CRC cohort samples and in the
methodological samples. The same array in version 2.0
was used for the PC cohort samples. The A-card (377
miRNAs) contained the same miRNA assays in the
two versions, whereas there were minor differences
between the B-cards. The instructions and reagents
from the manufacturer were used in all steps (http://
www.lifetechnologies.com/). Briefly, the procedure uti-
lized for the array analysis was as follows. RNA was
reverse transcribed (RT) using the TaqMan® Micro-
RNA Reverse Transcription Kit into cDNA in two
multiplex reactions each containing 3 μl of the small
RNA preparation, corresponding to 200 ng total RNA,
and either Megaplex RT Primer Pool A or Pool B in a
total reaction volume of 7.5 μl. The RT reaction was
run at 16 °C for 2 min, 42 °C for 1 min, and 50 °C for
1 sec for 40 cycles, then at 85 °C for 5 min, and held
at 4 °C. Prior to loading the arrays, a 12-cycle pre-
amplification reaction was performed using 2.5 μl
cDNA in a 25-μl reaction and using Megaplex PreAmp
Primers Pool A or B. The preamplification was run at
95 °C for 10 min, 55 °C for 2 min, 72 °C for 2 min, and
then 12 cycles at 95 °C for 15 sec and 60 °C for 4 min,
and finally 99.9 °C for 10 min and held at 4 °C. The
preamplified solution was then diluted with 75 μl 0.1x
TE buffer to a total volume of 100 μl. Each of the
arrays was loaded with 1/50 (8 μl) of the preamplifica-
tion reaction which was mixed with TaqMan Gene
Expression Master Mix in a total reaction volume of
800 μl and run on the 7900HT Fast Real-Time PCR
System. The PCR reaction was run using the same
program as for the RT. The quantification cycle (Cq)
was defined as the fractional cycle number at which
the fluorescence passed the fixed threshold. All raw Cq
values >32 were discarded. MiRNA expression values
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corresponded to higher expression. Data from samples
that had been analyzed in spite of a 260/280 nm
absorbance ratio <1.8 were removed from the final
data set. Data from methodological samples with a
260/230 nm absorbance ratio <1.5 were also removed.
The technical replicates were all from the same purifi-
cation, and they were analyzed on the same day on the
same machine, consecutively.
Statistical analysis
Normalization: Global mean miRNA expression was de-
fined as the sample-wise arithmetic mean Cq of all in-
cluded miRNA measurements. In analyses in which low
expression measurements and inconsistently expressed
miRNAs were removed, only the remaining measure-
ments were used to calculate global mean. Global mean
normalization was performed as previously described
[10]. Briefly, the mean of all Cq values for sample “i”
(global mean) was subtracted from each individual Cq
value from sample “i”. Normalization using reference
miRNAs was performed in a similar manner using the
arithmetic mean of the reference miRNAs instead of the
global mean.
Identification of reference miRNAs (CRC cohort and PC
cohort)
Calculations were performed separately for each tumor
type. Only miRNAs with less than 5 % missing values
were considered. Missing/undetermined = no signal
after 40 PCR cycles. A list of 20 miRNAs with the best
correlation to global mean miRNA expression was
identified using Spearman's rank correlation coefficient,
rs. The association between the expression of each of
the 20 miRNAs and OS was investigated using a Cox
proportional hazards (CPH) model [19, 20] to test if the
expression of individual candidate reference miRNAs
was independent of prognosis. The stability measure M
was calculated for each of the 20 miRNA according to
the formula by Vandesompele et al.[21]. If more than
one miRNA from the same miRNA family was included
in the list, only the miRNA with the lowest M value
was kept (miRNA family list found at http://www.mir-
base.org/ftp.shtml). Removing miRNAs from the same
family is recommended because miRNAs from the
same family are expected to be co-regulated [21, 22].
Consequently, adding additional co-regulated reference
genes would not significantly improve the combined
value of the genes as normalizers. The optimal number
of reference miRNAs to use was then calculated using
the pairwise variation measure V as described by
Vandesompele et al. [21], and Chang et al. [11]. V =
0.15 has been suggested as a suitable threshold below
which the inclusion of additional reference miRNAs isnot required, i.e. addition of further reference miRNAs
will not significantly improve stability [21].
The performance of previously identified candidate
prognostic miRNAs for each cancer type [16, 18] was
tested by analyzing the association between OS and
expression of the candidate prognostic miRNAs using
both global mean normalization and normalization with
the identified reference miRNAs.Effect of sample age (CRC cohort and PC cohort)
Global mean miRNA expression was plotted for each
sample according to the age of the tumor block, and the
effect of age was estimated using linear regression with
age as a continuous variable.Methodological samples
Correlations between related samples were described
using correlation coefficients, rs. Linear mixed effects
models with miRNA and samples as random effects
were used to quantify technical variability corresponding
to the between-sample and within-sample variation and
were reported as standard deviations (SD) in Cq. SDs
after normalization with global mean [10], the mean of
the optimal group of miRNAs, or the mean of the two
best reference miRNAs were also calculated. Hierarch-
ical clustering was performed using the miRNAs mea-
sured on all samples. Euclidean distance and complete
linkage were used with four different normalization
strategies: raw values (no normalization), global mean,
mean of optimal reference miRNAs, and mean of the
two best reference miRNAs. Additionally, 1-Pearson cor-
relation was used as distance metric. Dendrograms were
made for each of the mentioned clustering procedures.
Clustering was performed using the function hclust in
the stats package in R, and clusters were defined by
cutreeDynamicTree in the package dynamic-TreeCut
[23]. P < 0.05 was considered statistically significant. The
statistical software package R [24] version 3.0.2 (www.r-
project.org) was used for all analyses. An overview of the
sample cohorts and associated analyses is presented in
Figure S1 in Additional file 1.Ethics
The study was approved by the Regional Scientific Ethics
Committee of the Capital Region of Denmark (http://
www.regionh.dk/vek, approval numbers: H-KA-20060181
and H-1-2010-081). The CRC study was a retrospective
study wherein the ethics committee waived the require-
ment for obtaining informed consent. The PC study in-
cluded participants prospectively and all participants
signed an informed consent form allowing for publication
of the results.
Table 1 Optimal number of reference miRNAs – colorectal
cancer
Number of miRNAs Va ΔVa miRNAs added Stability
increased?
2 – – miR-103a-3p,
miR-152-3p
–
3 vs 2 0.3475 – miR-132-3p –
4 vs 3 0.1400 -0.2075 miR-27a-3p yes
5 vs 4 0.1728 0.0328 miR-140-5p no
6 vs 5 0.1145 -0.0583 miR-30b-5p yes
7 vs 6 0.1189 0.0044 miR-339-5p no
8 vs 7 0.1005 -0.0185 miR-331-3p yes
9 vs 8 0.0991 -0.0014 miR-374a-5p yes
10 vs 9 0.0778 -0.0212 miR-652-3p yes
11 vs 10 0.0689 -0.0089 miR-335-5p yes
12 vs 11 0.0728 0.0040 miR-185-5p no
13 vs 12 0.0588 -0.0140 miR-151-5p yes
14 vs 13 0.0614 0.0025 miR-106b-5p no
15 vs 14 0.0503 -0.0111 miR-199a-3p yes
16 vs 15 0.0574 0.0071 miR-425-5p no
17 vs 16 0.0426 -0.0147 miR-26a-5p yes
18 vs 17 0.0685 0.0259 miR-24-3p no
MiRNAs in bold are the ones that are included in the optimal number of
references to use.
aThe stability measure V is calculated according to Vandesompele et al. [21]
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Quality assessment
The median RNA yield from the purification of FFPE
and frozen samples were 3.3 μg and 33.4 μg, respect-
ively. Seventy-four clinical samples (6 CRC and 68 PC
samples) had a 260/280-ratio <1.8, leaving 197 CRC
samples and 188 PC samples for further analyses. After
first removing all Cq values above 32 and then remov-
ing miRNAs with more than 5 % undetermined mea-
surements, 199 miRNAs (CRC) and 179 miRNAs (PC)
were left for reference miRNA- and sample age analysis.
Five methodological samples were excluded based on
260/280 nm or 260/230 nm ratio and an additional fro-
zen sample was excluded because no comparison FFPE
blocks were left (Table S1 in Additional file 1). Corre-
sponding raw miRNA expression data, sample age, and
survival data are provided in Datasets S1–S3 in
Additional file 2, Additional file 3, and Additional file 4,
respectively.
Identification of reference miRNAs
The 20 miRNAs that correlated best with global mean
miRNA expression within each cancer type are listed in
Table S2 and S3 in Additional file 1, ordered by their
stability score. A few of the miRNAs were associated
with OS, but the hazard ratio (HR) estimates for these
miRNAs were close to the HR estimate of global mean
miRNA expression. Even though the identified reference
miRNAs differed between cancer types, nine miRNAs
were identified in both cancer types, namely: miR-24-3p,
miR-26a-5p, miR-27a-3p, miR-28-5p, miR-103a-3p, miR-
106b-5p, miR-152-3p, miR-199a-3p, and miR-374a-5p.
The following miRNAs were not considered in the cal-
culation of the optimal number of miRNAs because they
were in the same miRNAs family as other miRNAs with
better stability scores: miR-30c-5p and miR-28-5p in
CRC, and miR-26a-5p, miR-130a-3p, miR-374a-5p, and
let-7f-5p in PC. The optimal number of reference miR-
NAs to use was 4 in CRC and 10 in PC (Table 1 and
Table 2). MiR-27a-3p and miR-103a-3p were included in
the optimal number of reference miRNAs in both cancer
types. Four reference miRNAs were adequate to reach
the suggested cut-off of V < 0.15 in both types of cancer
samples.
The ratio of CRC reference miRNA expression (n = 4)
to global mean miRNA expression was independent of
tumor cell percentage (Figure S2 in Additional file 1). The
correlation between the top four PC reference miRNAs
and global mean miRNA expression was similar in tissue
samples from PC, normal pancreas, and chronic pancrea-
titis (Figure S3 in Additional file 1). Moreover, when we
used the same methodology as mentioned above to iden-
tify reference miRNAs in samples from normal pancreas
(n = 20) or chronic pancreatitis (n = 20) alone, many of thesame candidate reference miRNAs as in the PC cohort
were found (Table S4 and S5 in Additional file 1). The es-
timated hazard ratios for previously identified candidate
prognostic miRNAs [16, 18] were comparable for global
mean normalization and normalization using the identi-
fied reference miRNAs (Table S6 in Additional file 1).
Effect of sample age
There was a trend toward lower global mean miRNA
expression with increasing sample age in both tumor types
(Fig. 1), but this effect was only significant in PC samples.
CRC samples were up to 12 years old, but most were 0–5
years old. The ages of PC samples were more evenly
distributed and ranged from 0 to more than 30 years. The
effect of age in PC samples was -0.05 Cq/year and highly
significant (p < 0.01). After global mean normalization,
only two miRNAs showed a significant effect of storage
time on expression in both cancer types. These were miR-
197-3p: -0.09 Cq/year (p = 0.02) in CRC and -0.04 Cq/year
(p < 0.01) in PC; and miR-425-5p: -0.05 Cq/year (p = 0.03)
in CRC and -0.02 Cq/year (p < 0.01) in PC.
Sources of variability
Two hundred miRNAs were determined in at least 95 %
of the methodological samples. Measurements of miRNA
expression in five samples from the same cDNA reaction
Table 2 Optimal number of reference miRNAs – pancreatic
cancer
Number of miRNAs Va ΔVa miRNAs added Stability
increased?
2 – – miR-103a-3p,
miR-374b-5p
–
3 vs 2 0.1884 – miR-361-5p –
4 vs 3 0.1328 -0.0556 let-7 g-5p yes
5 vs 4 0.1141 -0.0186 miR-28-5p yes
6 vs 5 0.0962 -0.0179 miR-29a-3p yes
7 vs 6 0.0831 -0.0131 miR-301a-3p yes
8 vs 7 0.0631 -0.0200 miR-340-5p yes
9 vs 8 0.0596 -0.0036 miR-27a-3p yes
10 vs 9 0.0522 -0.0073 miR-106b-5p yes
11 vs 10 0.0527 0.0005 miR-152-3p no
12 vs 11 0.0549 0.0021 miR-26b-5p no
13 vs 12 0.0464 -0.0084 miR-660-5p yes
14 vs 13 0.0470 0.0006 miR-24-3p no
15 vs 14 0.0517 0.0047 miR-23b-3p no
16 vs 15 0.0569 0.0052 miR-199a-3p no
MiRNAs in bold are the ones that are included in the optimal number of
references to use.
a The stability measure V is calculated according to Vandesompele et al. [21]
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0.996 (Table 3 and Fig. 2). The total variation in SD in a
miRNA expression measurement was 0.31 Cq with equal
contributions from within- and between-sample variation.
MiRNA expression in the five samples sectioned from ad-
jacent areas of the same tumor block ("biological repli-
cates") also showed a strong correlation: rs = 0.98–0.99
(Fig. 3). The SD on a miRNA expression measurement
was 0.52 Cq for the biological replicates. The correlations
between the three other pairs of biological replicates wereFig. 1 Association between sample age and global mean miRNA expressio
plotted on the x-axis and global mean miRNA expression in 40-Cq values o
is shown.0.99, 0.93, and 0.99. This should be compared to the
median correlation between unrelated samples, i.e. the
inter-individual correlation, which was 0.88. Global mean
normalization lowered the SD to 0.24 Cq (technical repli-
cates) and 0.42 Cq (biological replicates). Paraffin embed-
ding and formalin fixation lowered the global mean
miRNA expression. The effect was smaller for 2-day
fixation: -0.50 Cq, than for 3- and 6-day fixation: -1.56 Cq
and -1.14 Cq, respectively. This corresponds to a reduction
of 30–65 % assuming 100 % PCR efficiency. The variability
between the frozen and differently formalin-fixed samples
was much greater than the variability observed for the bio-
logical replicates taken from the same FFPE block, but the
mean correlation was still high (Table 3). With the excep-
tion of the comparison between technical replicates, using
the two best reference miRNAs (miR-103a-3p and miR-
152-3p) or the previously identified optimal number of
reference miRNAs (n = 4) for normalization also tended to
lower the SD, although to a lesser degree than with global
mean normalization (Table 3).
Hierarchical clustering
One hundred and seventy-four miRNAs were determined
in all the 31 methodological samples and only these miR-
NAs were used for clustering. Clustering dendrograms are
shown in Figures S4–S8 in Additional file 1. Using 1-
Pearson correlation as a distance metric, 87 % of samples
clustered together with at least one other sample from the
same tumor. Using Euclidean distance on the raw expres-
sion data, 74 % of samples clustered with at least one
other sample from the same tumor. This percentage im-
proved numerically with normalization using global mean,
optimal number of reference miRNAs (n = 4), and the two
best reference miRNAs (miR-103a-3p and miR-152-3p) to
90 %, 81 %, and 84 %, respectively. Two pairs of biologicaln for CRC (left) and PC (right) samples. Age of the tumor blocks are
n the y-axis. A linear regression line has been plotted and the formula
Table 3 Variability in miRNA expression measurements: technical replicates, biological replicates, and frozen versus FFPE tissue
Variability, SD (Cq)
Correlationa, rs Raw data Total variability with normalized data
Samples median (range) Individual miRNA Inter-sample Total Global mean Optimal number of refs.
(n = 4)
Two best refs.
Technical replicates 5 0.995 (0.993–0.996) 0.24 0.19 0.31 0.24 0.32 0.40
Biological replicates 4 0.985 (0.98–0.99)b 0.42 0.30 0.52 0.42 0.46 0.49
Frozen vs. FFPE 17c 0.92 (0.66–0.96) 1.35 1.00 1.68 1.18 1.35 1.31
a For frozen versus FFPE, the correlations were calculated between formalin-fixed and corresponding frozen samples (12 total correlations).
b The median correlation between unrelated biological replicates, i.e. the inter-individual correlation, was 0.88 (range 0.84–0.91).
c Sample distribution: 5 frozen, 4 x 2-day fixation, 5 x 3-day fixation, and 3 x 6-day fixation.
Abbreviations: FFPE, formalin-fixed paraffin-embedded; SD, standard deviation; Cq, quantification cycle; rs, Spearman's rank correlation coefficient; refs., references.
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used, but did so in all of the normalized data dendro-
grams. Frozen samples from different tumors tended to
cluster together.
Repeat analysis using all measurements
To address the potential bias introduced by removing low
expression measurements, we repeated all analyses without
removal of any measurements. The addition of low expres-
sion measurements resulted in an increased variability
between replicates that could not be lowered by
normalization (Table S7 in Additional file 1). The small de-
crease in global mean miRNA expression with increasing
sample age was still present (CRC: -0.07 Cq/year, p = 0.03;
PC: -0.02 Cq/year, p < 0.01). There was a high correlation
between high-quality means (measurements with Cq > 32Fig. 2 Correlation between miRNA expression profiles measured in five run
with axes showing miRNA expression in 40-Cq values. The sample numbersand miRNAs with >5 % undetermined removed) and low-
quality means (no measurements removed) (Figure S9 in
Additional file 1). The list of candidate reference miRNAs
identified using all measurements was similar to the list
identified using high quality measurements (Additional file
1: Table S8 and S9). Of note, miR-103a-3p was still the
most stable or third most stable reference miRNA.
Discussion
MiRNAs hold great promise as biomarkers for the diagno-
sis, prognosis, and prediction of treatment benefit in pa-
tients with cancer, and they are also potential targets for
new cancer drugs. In order to utilize miRNAs for these
purposes, it is paramount to first learn about the precise
dysregulation of individual miRNAs in various disease
states. To this end, optimal normalization is essential. Ins from the same purification. Correlations are illustrated by a pairs plot
correspond to the project IDs in Table S1 in Additional file 1.
Fig. 3 Correlation between miRNA expression profiles measured in four samples from the same tumor block. Correlations are illustrated by a
pairs plot with axes showing miRNA expression in 40-Cq values. The sample numbers correspond to the project IDs in Table S1 in Additional
file 1.
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the established standard. But in studies with fewer miR-
NAs, normalization with stable global mean-associated
reference miRNAs is the best option [10–15].
To the best of our knowledge, we have presented
in this study the first unbiased identification of
stable miRNA reference genes in FFPE cancer tissue.
This is also the first study to identify miRNA refer-
ence genes in PC tissue, and it is the largest study
of its kind to date. Normalization with the selected
CRC reference miRNAs was able to slightly reduce
variability between biological replicates and between
frozen and FFPE samples, and it improved hierarch-
ical clustering results. The reason why the reference
miRNAs did not decrease variability for technical
replicates could be that the variability in the raw
data was very low. As shown in Table S4 in
Additional file 1, 10 out of the 20 candidate refer-
ence miRNAs for CRC tissue and 8 out of the 20
candidate reference miRNAs for PC tissue have been
identified as stable global mean-associated reference
miRNAs in previous studies on frozen samples. In
fact, at least one reference miRNA from each of the
previously reported studies was represented in our
top-20 lists (Table S4 in Additional file 1). This indi-
cates that some reference miRNAs are suitable for
normalization of both frozen- and FFPE samples,
which has been suggested previously [12].Reference miRNAs are not necessarily equally suited
for normalization of miRNA expression in cancer cells
and in normal cells. However, the expression of the
identified CRC reference miRNAs was independent of
tumor cell content. Moreover, the expression of the
identified PC reference miRNAs was strongly corre-
lated with global mean miRNA expression in both
cancer and non-cancer samples. Therefore, these ref-
erence miRNAs could be suitable for normalization
regardless of the ratio of tumor- versus normal cells in
the sample. Further, several of the candidate reference
miRNAs we identified have previously been shown to
be stably expressed in normal tissue from multiple
organs [10, 12, 14]. The most stable global mean-
associated miRNA in both of our cohorts was miR-
103a-3p. This miRNA has also been identified as a
stable normalizer in frozen kidney and lung cancer
samples [12, 13]. Interestingly, in the study by Peltier
et al. [12], the authors found that miR-103a-3p was
only the fourth most stable reference miRNA in frozen
lung cancer tissue, while it was the most stable refer-
ence miRNA in FFPE lung cancer tissue. Thus, this
miRNA could be especially suitable for normalization
in FFPE cancer tissue. In the same study, miR-16 – a
commonly used reference miRNA – was the least
stable of seven candidate miRNAs in both frozen and
FFPE lung cancer samples. MiR-16 was not identified
as a candidate reference miRNA in our study, and its
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uncertain.
We identified a significant but modestly sized de-
crease in miRNA expression as a function of storage
time in PC. The trend was similar in CRC samples, but
it was not significant. The effect in PC amounts to a
50 % reduction of the miRNA expression over 20 years.
Siebolts et al. found a very similar rate of decline of
miR-16 expression in FFPE blocks stored for up to
27 years [25]. An effect of this size should not have a
detrimental impact on the use of FFPE samples for clin-
ical biomarkers in PC or CRC, because these samples
are often only a few months to a couple of years old
when used. Also, normalization would mitigate some of
the difference, as demonstrated in two other studies in
which the authors did not see any effect of storage time
in miRNA expression normalized to RNU6B or to other
miRNAs [26, 27].
An excellent reproducibility of the chosen platform
was demonstrated with highly correlated miRNA expres-
sion in technical replicates. The biological replicates
were different sections from the same tumor block. The
variability in these replicates is the sum of biological dif-
ferences in the tumor block and variability in sectioning,
purification, reverse transcription, and amplification.
Even with all these additional sources of variability, we
found an excellent correlation between these samples,
with only a minor increase in SD, from 0.31 to 0.52 Cq,
compared to the technical variability caused by the amp-
lification process alone. This suggests that miRNA ex-
pression is not very heterogeneous within an FFPE
tumor block.
Formalin fixation and paraffin embedding caused a
decline in miRNA expression of between 0.5 and ~1.5
Cq; yet, correlation between miRNA expression in fro-
zen- and FFPE tissue from the same tumor was still
high. Hoefig et al. also found a 1.0–1.5 Cq decline in
miRNA expression in formalin-fixed compared to fro-
zen liver- and tonsil samples [28]. The decrease in glo-
bal mean miRNA expression could be a result of
miRNA degradation, excessive fixation of miRNA in
the FFPE tissue with suboptimal purification, or small
fragmented ribosomal- and messenger RNA interfer-
ing with the miRNA signal on the array. Many previ-
ous studies have reported a good correlation between
frozen- and FFPE samples [28–32]. The variability be-
tween frozen and FFPE samples was high in our study,
and frozen samples from different tumors tended to
cluster together in the hierarchical clustering analysis.
Moreover, global mean normalization did not greatly
improve the clustering of frozen samples. These find-
ings could be a result of formalin-fixation causing
non-uniform changes in miRNA measurability. They
highlight the importance of doing large scale studiesin both frozen and FFPE samples and not relying on
direct portability of results between the two.
The quality of the purified RNA was lower in the PC co-
hort than in the CRC cohort, resulting in a higher propor-
tion of excluded samples in the PC cohort. The PC
samples were purified and analyzed in smaller batches dis-
tributed over a longer period compared to the CRC sam-
ples, which could have decreased overall quality of this
sample cohort. In addition, the purification kit used for
the PC cohort, which differed from the kit used in the
CRC cohort, could have been less effective. Finally, the
samples in the PC cohort were older which could also
have influenced RNA quality.Conclusions
Low expression measurements (Cq > 32) were removed
before undertaking the analyses. This was done to re-
duce noise in the data, but it could also introduce a
bias to the results. Therefore, all of the analyses were
repeated without removal of low expression measure-
ments, but this did not result in any major changes in
the results, apart from the anticipated increase in vari-
ability. It is also important to note that several different
technologies are used for miRNA expression quantifica-
tion apart from RT-qPCR, e.g. hybridization-based ar-
rays and sequencing technologies [33], and our findings
may not be applicable to all such technologies. In sum-
mary, we have identified stable global mean-associated
reference miRNAs for use in miRNA expression studies
on FFPE cancer tissue from patients with colorectal
and pancreatic cancer. This is the first study to search
specifically for reference miRNAs for use in FFPE can-
cer tissue. We also found that the length of storage is
not a significant determinant of miRNA abundance in
FFPE cancer tissue and that intra-block miRNA expres-
sion heterogeneity seems to be low. Formalin fixation
caused a decline in miRNA expression, but expression
profiles from frozen and FFPE samples from the same
tumor were generally still highly correlated. These re-
sults should provide valuable information for the plan-
ning and execution of future miRNA biomarker studies
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